After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.
Roslyn A. Stone, PhD
Advertisement
Articles by Roslyn A. Stone, PhD
Advertisement
Latest Updated Articles
- Implementation of an Inpatient Management and Discharge Strategy for Patients With Community-acquired Pneumonia
Published: August 1st 2005 | Updated:
- FDA Warning and Removal of Rosiglitazone From VA National Formulary
Published: September 19th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Value-Based Care Interventions and Management of CKD Progression
5
